Israel may lose leadership in medical research

Kobi Tsoref, head of the Pharma Israel association, warned that Israel may lose its leadership in clinical research due to growing competition and bureaucratic barriers. Research brings hospitals about 700 million shekels a year. Tsoref called on the government to speed up approval procedures.

Israel may lose its leadership in clinical research, threatening hospital revenues and patient access to new treatments. This warning was issued by Kobi Tsoref, CEO of the Pharma Israel association, at a healthcare conference on November 17. Clinical research brings Israeli hospitals about 700 million shekels a year. Tsoref called on the government to remove bureaucratic barriers and speed up approval procedures, noting that China, the US, and the UK are actively investing in this field. In October, the government approved a 25 million shekel program for 2026-2027 to remove regulatory barriers. Tsoref emphasized that research that leaves Israel will not return, and action must be taken immediately.

Israel may lose leadership in medical research